title: Long-term results of stereotactic radiosurgery in secretory pituitary adenomas.
abstract: BACKGROUND
  To date, no study reported long-term follow-up results of gamma knife stereotactic radiosurgery (SR).
  
  
  OBJECTIVE
  The aim of the study was to determine long-term efficacy and adverse effects of SR in secreting pituitary adenomas.
  
  
  METHODS
  We conducted a retrospective study of patients treated by SR in the center of Marseille, France, with a follow-up of at least 60 months.
  
  
  METHODS
  A total of 76 patients were treated by SR for acromegaly (n = 43), Cushing's disease (CD; n = 18), or prolactinoma (n = 15) as a primary (n = 27) or adjunctive postsurgical treatment (n = 49).
  
  
  METHODS
  After withdrawal of antisecretory drugs, patients were considered in remission if they had mean GH levels below 2 ng/ml and normal IGF-I (acromegaly), normal 24-h urinary free cortisol, and cortisol less than 50 nmol/liter after low-dose dexamethasone test (CD) or two consecutive normal samplings of prolactin levels (prolactinoma).
  
  
  RESULTS
  After a mean follow-up of 96 months, 44.7% of the patients were in remission. Mean time to remission was 42.6 months. Twelve patients presented late remission at least 48 months after SR. Two patients with CD presented late recurrence 72 and 96 months after SR. Forty percent of patients treated primarily with SR were in remission. Target volume and initial hormone levels were significant predictive factors of remission in univariate analysis. Radiation-induced hypopituitarism was observed in 23% patients; in half of them, hypopituitarism was observed after a mean time of 48 to 96 months. Twenty-four patients were followed for more than 120 months; rates of remission and hypopituitarism were similar to the whole cohort.
  
  
  CONCLUSIONS
  SR is an effective and safe primary or adjunctive treatment in selected patients with secreting pituitary adenomas.
authors.affiliation: Service d'Endocrinologie, Diabète, et Maladies Métaboliques, et Centre de Reference des Maladies Rares d'Origine Hypophysaires, Hôpital de la Timone, F-13385 Marseille, France.
authors.forename: Frederic
authors.initials: F
authors.lastname: Castinetti
authors.forename: Mariko
authors.initials: M
authors.lastname: Nagai
authors.forename: Isabelle
authors.initials: I
authors.lastname: Morange
authors.forename: Henry
authors.initials: H
authors.lastname: Dufour
authors.forename: Philippe
authors.initials: P
authors.lastname: Caron
authors.forename: Philippe
authors.initials: P
authors.lastname: Chanson
authors.forename: Christine
authors.initials: C
authors.lastname: Cortet-Rudelli
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Kuhn
authors.forename: Bernard
authors.initials: B
authors.lastname: Conte-Devolx
authors.forename: Jean
authors.initials: J
authors.lastname: Regis
authors.forename: Thierry
authors.initials: T
authors.lastname: Brue
mesh_terms: D000172:Acromegaly / Q000601:surgery; D000236:Adenoma / Q000378:metabolism / Q000601:surgery*; D000293:Adolescent; D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000368:Aged; D002648:Child; D005260:Female; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D047748:Pituitary ACTH Hypersecretion / Q000601:surgery; D010911:Pituitary Neoplasms / Q000378:metabolism / Q000601:surgery*; D011388:Prolactin / Q000378:metabolism; D015175:Prolactinoma / Q000601:surgery; D016634:Radiosurgery / Q000009:adverse effects; D012189:Retrospective Studies
chemical_list: D019382:Human Growth Hormone; D000324:Adrenocorticotropic Hormone; D011388:Prolactin